Versican expression in tumor epithelial cells is correlated with a good prognosis in gastric cancer

Anticancer Research

Volumn 34, Issue 10, 2014, Pages 5613-5619

  Kim, Nam Seok ^a   Lee, Han Hong ^a   Jung, Chan Kwon ^b   Jeon, Hae Myung ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

Epithelial cells; Stomach neoplasm; Stromal cells; Versican

Indexed keywords

VERSICAN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CYTOPLASM; DISEASE FREE SURVIVAL; EPITHELIUM CELL; FEMALE; FIBROBLAST; GASTRECTOMY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERINEURAL INVASION; PROTEIN EXPRESSION; STOMACH CANCER; STROMA CELL; TUMOR EPITHELIUM CELL; VERY ELDERLY; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PATHOLOGY; PROGNOSIS; STOMACH MUCOSA; STOMACH TUMOR;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GASTRIC MUCOSA; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; STOMACH NEOPLASMS; VERSICANS;

EID: 84917742642     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Oue N, Sentani K, Sakamoto N, Motoshita J, Nishisaka T, Fukuhara T, Matsuura H, Sasaki H, Nakachi K and Yasui W: Characteristic gene expression in stromal cells of gastric cancers among atomic-bomb survivors. Int J Cancer 124: 1112-1121, 2009.
2. Hartgrink HH, Jansen EP, van Grieken NC and van de Velde CJ: Gastric cancer. Lancet 374: 477-490, 2009.
3. Ricciardelli C and Rodgers RJ: Extracellular matrix of ovarian tumors. Semin Reprod Med 24: 270-282, 2006.
4. Ricciardelli C, Sakko AJ, Ween MP, Russell DL and Horsfall DJ: The biological role and regulation of versican levels in cancer. Cancer Metastasis Rev 28: 233-245, 2009.
5. Voulgari A and Pintzas A: Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 1796: 75-90, 2009.
6. Du C, Zhang C, Hassan S, Biswas MH and Balaji KC: Protein kinase D1 suppresses epithelial-to-mesenchymal transition through phosphorylation of snail. Cancer Res 70: 7810-7819, 2010.
7. Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890, 2009.
8. Kwok JC, Afshari F, Garcia-Alias G and Fawcett JW: Proteoglycans in the central nervous system: plasticity, regeneration and their stimulation with chondroitinase ABC. Restor Neurol Neurosci 26: 131-145, 2008.
9. LeBaron RG, Zimmermann DR and Ruoslahti E: Hyaluronate binding properties of versican. J Biol Chem 267: 10003-10010, 1992.
10. Yamagata M, Yamada KM, Yoneda M, Suzuki S and Kimata K: Chondroitin sulfate proteoglycan (PG-M-like proteoglycan) is involved in the binding of hyaluronic acid to cellular fibronectin. J Biol Chem 261: 13526-13535, 1986.
11. Voutilainen K, Anttila M, Sillanpaa S, Tammi R, Tammi M, Saarikoski S and Kosma VM: Versican in epithelial ovarian cancer: relation to hyaluronan, clinicopathologic factors and prognosis. Int J Cancer 107: 359-364, 2003.
12. Suwiwat S, Ricciardelli C, Tammi R, Tammi M, Auvinen P, Kosma VM, LeBaron RG, Raymond WA, Tilley WD and Horsfall DJ: Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res 10: 2491-2498, 2004.
13. Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, McCaul K, Marshall VR and Horsfall DJ: Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. Clin Cancer Res 4: 963-971, 1998.
14. Du WW, Fang L, Yang X, Sheng W, Yang BL, Seth A, Zhang Y, Yang BB and Yee AJ: The role of versican in modulating breast cancer cell self-renewal. Mol Cancer Res 11: 443-455, 2013.
15. Kodama J, Hasengaowa, Kusumoto T, Seki N, Matsuo T, Ojima Y, Nakamura K, Hongo A and Hiramatsu Y: Prognostic significance of stromal versican expression in human endometrial cancer. Ann Oncol 18: 269-274, 2007.
16. Ghosh S, Albitar L, LeBaron R, Welch WR, Samimi G, Birrer MJ, Berkowitz RS and Mok SC: Up-regulation of stromal versican expression in advanced stage serous ovarian cancer. Gynecol Oncol 119: 114-120, 2010.
17. Takahashi Y, Kuwabara H, Yoneda M, Isogai Z, Tanigawa N and Shibayama Y: Versican G1 and G3 domains are upregulated and latent transforming growth factor-beta binding protein-4 is downregulated in breast cancer stroma. Breast Cancer 19: 46-53, 2012.
18. Kodama J, Hasengaowa, Kusumoto T, Seki N, Matsuo T, Nakamura K, Hongo A and Hiramatsu Y: Versican expression in human cervical cancer. Eur J Cancer 43: 1460-1466, 2007.
19. Cai Y, Balli D, Ustiyan V, Fulford L, Hiller A, Misetic V, Zhang Y, Paluch AM, Waltz SE, Kasper S and Kalin TV: Foxm1 expression in prostate epithelial cells is essential for prostate carcinogenesis. J Biol Chem 288: 22527-22541, 2013.
20. Pirinen R, Leinonen T, Bohm J, Johansson R, Ropponen K, Kumpulainen E and Kosma VM: Versican in nonsmall cell lung cancer: relation to hyaluronan, clinicopathologic factors, and prognosis. Hum Pathol 36: 44-50, 2005.
21. Varga I, Hutoczki G, Szemcsak CD, Zahuczky G, Toth J, Adamecz Z, Kenyeres A, Bognar L, Hanzely Z and Klekner A: Brevican, neurocan, tenascin-C and versican are mainly responsible for the invasiveness of low-grade astrocytoma. Pathol Oncol Res 18: 413-420, 2014.
22. Ang LC, Zhang Y, Cao L, Yang BL, Young B, Kiani C, Lee V, Allan K and Yang BB: Versican enhances locomotion of astrocytoma cells and reduces cell adhesion through its G1 domain. J Neuropathol Exp Neurol 58: 597-605, 1999.
23. Pukkila M, Kosunen A, Ropponen K, Virtaniemi J, Kellokoski J, Kumpulainen E, Pirinen R, Nuutinen J, Johansson R and Kosma VM: High stromal versican expression predicts unfavourable outcome in oral squamous cell carcinoma. J Clin Pathol 60: 267-272, 2007.
24. de Wit M, Belt EJ, Delis-van Diemen PM, Carvalho B, Coupe VM, Stockmann HB, Bril H, Belien JA, Fijneman RJ and Meijer GA: Lumican and versican are associated with good outcome in stage II and III colon cancer. Ann Surg Oncol 20(Suppl 3): S348-359, 2013.
25. Lee JM, Dedhar S, Kalluri R and Thompson EW: The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172: 973-981, 2006.
26. Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428, 2009.
27. Polyak K and Weinberg RA: Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9: 265-273, 2009.
28. Naso MF, Zimmermann DR and Iozzo RV: Characterization of the complete genomic structure of the human versican gene and functional analysis of its promoter. J Biol Chem 269: 32999-33008, 1994.
29. Zimmermann DR and Ruoslahti E: Multiple domains of the large fibroblast proteoglycan, versican. EMBO J 8: 2975-2981, 1989.
30. Matsumoto K, Shionyu M, Go M, Shimizu K, Shinomura T, Kimata K and Watanabe H: Distinct interaction of versican/PGM with hyaluronan and link protein. J Biol Chem 278: 41205-41212, 2003.
31. Kawashima H, Li YF, Watanabe N, Hirose J, Hirose M and Miyasaka M: Identification and characterization of ligands for L-selectin in the kidney. I. Versican, a large chondroitin sulfate proteoglycan, is a ligand for L-selectin. Int Immunol 11: 393-405, 1999.
32. Kawashima H, Hirose M, Hirose J, Nagakubo D, Plaas AH and Miyasaka M: Binding of a large chondroitin sulfate/dermatan sulfate proteoglycan, versican, to L-selectin, P-selectin, and CD44. J Biol Chem 275: 35448-35456, 2000.
33. Wu Y, Chen L, Zheng PS and Yang BB: beta 1-Integrin-mediated glioma cell adhesion and free radical-induced apoptosis are regulated by binding to a C-terminal domain of PG-M/versican. J Biol Chem 277: 12294-12301, 2002.
34. Hirose J, Kawashima H, Yoshie O, Tashiro K and Miyasaka M: Versican interacts with chemokines and modulates cellular responses. J Biol Chem 276: 5228-5234, 2001.
35. Perissinotto D, Iacopetti P, Bellina I, Doliana R, Colombatti A, Pettway Z, Bronner-Fraser M, Shinomura T, Kimata K, Morgelin M, Lofberg J and Perris R: Avian neural crest cell migration is diversely regulated by the two major hyaluronan-binding proteoglycans PG-M/versican and aggrecan. Development 127: 2823-2842, 2000.
36. Zheng PS, Wen J, Ang LC, Sheng W, Viloria-Petit A, Wang Y, Wu Y, Kerbel RS and Yang BB: Versican/PG-M G3 domain promotes tumor growth and angiogenesis. FASEB J 18: 754-756, 2004.
37. Paris S, Sesboue R, Chauzy C, Maingonnat C and Delpech B: Hyaluronectin modulation of lung metastasis in nude mice. Eur J Cancer 42: 3253-3259, 2006.
38. Chang MY, Tanino Y, Vidova V, Kinsella MG, Chan CK, Johnson PY, Wight TN and Frevert CW: A rapid increase in macrophage-derived versican and hyaluronan in infectious lung disease. Matrix Biol, 2014.
39. Nikitovic D, Zafiropoulos A, Katonis P, Tsatsakis A, Theocharis AD, Karamanos NK and Tzanakakis GN: Transforming growth factor-beta as a key molecule triggering the expression of versican isoforms v0 and v1, hyaluronan synthase-2 and synthesis of hyaluronan in malignant osteosarcoma cells. IUBMB Life 58: 47-53, 2006.